# Damora Therapeutics, Inc. (DMRA)

> Source: Nexqual · https://nexqual.com/DMRA · data as of 2026-10-29 20:00 UTC · cite as "Nexqual, Damora Therapeutics, Inc. (DMRA), nexqual.com/DMRA" · informational, not investment advice.

**Price:** USD 22.01 (+1.85% on the day) · last close of Oct 29, 2026; US market closed, not a live price. Prev close 21.61 · day 21.5–23.21 · 52w 4.95–38.33 · market cap $1.36B · NCM

## Key facts
- 1 of 80 tracked superinvestors hold DMRA (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $7K; 1 not under a Rule 10b5-1 plan ($7K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Insider open-market purchases, last ~7 months: 1 Form 4 filing, $253K; 0 by opportunistic insiders, 0 by routine insiders.
- Analysts: Buy (mean 1.90 on a 1–5 scale) (10 analysts), mean target USD 46.89 (range 40–60).
- Total return with dividends: 1Y +194.0% vs S&P 500 +14.8%; 5Y -73.3% vs S&P 500 +79.1%.
- Next earnings: 2026-11-05 (date not yet confirmed by the company), EPS estimate USD -0.44, revenue estimate $0K. All companies reporting that day: https://nexqual.com/earnings/2026-11-05
- Dividend: DMRA paid no cash dividend in the last five years.
- Short interest: 9.74% of float (as of 2026-10-15), 6.7 days to cover.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Operating income | -$52.2M | -$61.2M | -$39.9M | -$22.3M | -$211M | -$271M |
| Net income | -$51.8M | -$61.6M | -$38.3M | -$21.4M | -$210M | -$263M |
| EPS (diluted) | -$51.25 | -$60.75 | -$36.08 | -$18.53 | $3.98 | — |
| Free cash flow | -$52.5M | -$43.1M | — | — | — | — |
| Cash + short-term investments | $100M | $60.2M | $33.2M | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/B 2.6x · Earnings yield -19.34%

## Superinvestors (SEC 13F-HR, Q2 2026)
1 of 80 tracked investors hold DMRA. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 0.17% | $60.1M | Unchanged |

## Insider sales (SEC Form 4, open-market, last ~7 months)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-06 | Winslow Garrett | General Counsel | 245 | $7K | 9.7% | No | Too little history (no open-market trades in 2023 or 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Insider purchases (SEC Form 4, open-market, last ~7 months)
1 purchase, $253K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.
| Trade date | Insider | Role | Shares | Value | Avg price | Insider type |
|---|---|---|---|---|---|---|
| 2026-09-25 | Jarrett Jennifer | Director, President and CEO | 12,500 | $253K | 20.23 | Too little history (no open-market trades in 2023–2025) |

## Analysts
Consensus Buy (mean 1.90 on a 1–5 scale), 10 analysts; mean target USD 46.89 (low 40, high 60).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Wedbush | Reiterated | Outperform | $40 |
| 2026-09-25 | Guggenheim | Target raised | Buy | $40 → $60 |
| 2026-07-30 | Wedbush | Target raised | Outperform | $35 → $40 |
| 2026-07-27 | Jefferies | Initiated | Buy | $50 |
| 2026-07-21 | HC Wainwright & Co. | Reiterated | Buy | $45 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-30) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | +194.0% | -73.3% |
| S&P 500 (SPY) | +14.8% | +79.1% |
| Per year | +196.0% | -23.2% |
| Volatility (annualized) | 163.4% | 148.9% |
| Max drawdown | -46.9% (Dec 2025→Mar 2026) | -97.4% (Nov 2021→Apr 2025) |

## Dividends
DMRA paid no cash dividend in the last five years.

## Short interest
5,152,194 shares sold short, 9.74% of the float, as of Oct 15, 2026 (exchange short-interest report, published about twice a month). Prior report (Sep 15, 2026): 4,732,463 shares (+8.9%). Days to cover: 6.7 (short shares ÷ average daily volume).

## Peers (Biotechnology)
ORKA (Oruka Therapeutics, Inc.) USD 96.65 +0.71% · LGND (Ligand Pharmaceuticals Incorpor) USD 317.33 -0.45% · IOVA (Iovance Biotherapeutics, Inc.) USD 9.56 -35.45% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.39 -1.14% · AXSM (Axsome Therapeutics, Inc.) USD 143.45 -0.04% · ABVX (Abivax SA) USD 89.06 -0.87%

## More
Full page: https://nexqual.com/DMRA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.43 | $-0.40 | −$0.04 | $0 | 4 |
| Next quarter (ends 2026-12-31) | $-0.47 | $-0.43 | −$0.04 | $0 | 4 |
| Current fiscal year (ends 2026-12-31) | $-1.90 | $-1.75 | −$0.14 | $0 | 4 |
| Next fiscal year (ends 2027-12-31) | $-2.17 | $-2.08 | −$0.09 | $0 | 4 |

## Earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| — | Quarter ended Jun 30, 2026 | −$0.39 | −$0.37 | Miss −5.4% | — |
| — | Quarter ended Sep 30, 2025 | −$2.36 | — | — | — |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

## Recent SEC filings (last 120 days)
| Filed | Form | What it says | Filing |
|---|---|---|---|
| 2026-08-10 | 10-Q | Quarterly report · period ended Jun 30, 2026 | https://www.sec.gov/Archives/edgar/data/1800315/000119312526342307/0001193125-26-342307-index.htm |
| 2026-07-28 | Schedule 13G | BlackRock, Inc.: 5.1% of shares, passive 5%+ holder | https://www.sec.gov/Archives/edgar/data/1800315/000201238326002507/0002012383-26-002507-index.htm |
| 2026-07-20 | 8-K | Entered a material agreement; Change to shareholder rights; Bylaws or fiscal-year change; Regulation FD disclosure — “On July 16, 2026, Damora Therapeutics, Inc., a Cayman Islands exempted company (the " Company "), entered into indemnification agreements with each of its directors and executive officers (collectively, the " Indemnitees " and, the " Indemnification Agreements "), which replaced and superseded any previous indemnification agreements between the Company and each such individual. The Indemnification Agreements provide for certain indemnification and advancement of expenses by the Company in connection with actions…” | https://www.sec.gov/Archives/edgar/data/1800315/000119312526308899/0001193125-26-308899-index.htm |
Source: SEC EDGAR. Quotes are the opening words of each item as filed.